Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | USP9X | Q93008 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 9/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.35 |
| ▸ | ITGAV | P06756 | 4/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.33 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29702401 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4USP9XCHRNA7ITGB3 | |
| SCHEMBL21314426 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4USP9XCHRNA7ITGB3 | |
| SCHEMBL20158249 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4USP9XCHRNA7ITGB3 | |
| SCHEMBL21314425 | 1.00 | ITGB1 (0.41) | ITGB1ITGA4USP9XCHRNA7ITGB3 | |
| SCHEMBL30487528 | 0.91 | LMNA (0.36) | ITGB1ITGA4USP9XCHRNA7KCNK3 | |
| SCHEMBL20158250 | 0.91 | LMNA (0.36) | ITGB1ITGA4USP9XCHRNA7KCNK3 | |
| SCHEMBL20142360 | 0.82 | ITGAV (0.53) | ITGB1ITGB3ITGA2BITGAVITGB5 | |
| SCHEMBL20142358 | 0.82 | ITGAV (0.53) | ITGB1ITGB3ITGA2BITGAVITGB5 | |
| SCHEMBL23404646 | 0.77 | ITGB1 (0.39) | ITGB1ITGA4USP9XKCNK3 | |
| SCHEMBL23404650 | 0.77 | ITGB1 (0.39) | ITGB1ITGA4USP9XKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | ITGB1 1/4885ITGA4 13/4885USP9X 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.